BioPlus KRX:099430KOSDAQ
바이오플러스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, BioPlus reported revenue of ₩25.4bn, up 22.9% year on year, and operating profit of ₩6.2bn. BioPlus (바이오플러스) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 11 with 1 article.
BioPlus quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩25.4bn | +22.9% | ₩6.2bn | ₩3.7bn |
| Q1 2026 | ₩26.5bn | +15.4% | ₩5.7bn | ₩8.0bn |
| Q4 2025 derived | ₩23.2bn | -20.3% | ₩963m | ₩3.6bn |
| Q3 2025 | ₩24.1bn | +46.5% | ₩4.9bn | ₩4.4bn |
| Q2 2025 | ₩20.7bn | +83.1% | ₩2.1bn | ₩3.4bn |
| Q1 2025 | ₩23.0bn | +139.1% | ₩7.1bn | ₩8.5bn |
| Q4 2024 derived | ₩29.1bn | +80.0% | ₩13.8bn | ₩4.5bn |
| Q3 2024 | ₩16.4bn | -6.3% | ₩4.7bn | ₩4.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
BioPlus top stories 2 weeks, by number of outlets
- 1